

263.22
263.23
263.24
263.25
263.26
263.27
263.28
263.29
263.30
264.1
264.2
264.3
264.4
264.5
264.6
264.7
264.8
264.9
264.10
264.11
264.12
264.13
264.14
264.15
264.16
264.17
264.18
264.19
264.20

ARTICLE 17

CONTROLLED SUBSTANCES SCHEDULES

Section 1. Minnesota Statutes 2022, section 152.02, subdivision 2, is amended to read:

Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following substances, including their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, and salts is possible:

- (1) acetylmethadol;
- (2) allylprodine;
- (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate);
- (4) alphameprodine;
- (5) alphasmethadol;
- (6) alpha-methylfentanyl benzethidine;
- (7) betacetylmethadol;
- (8) betameprodine;
- (9) betamethadol;
- (10) betaprodine;
- (11) clonitazene;
- (12) dextromoramide;
- (13) diampromide;
- (14) diethylambutene;
- (15) difenoxin;
- (16) dimenoxadol;
- (17) dimepheptanol;
- (18) dimethylambutene;
- (19) dioxaphetyl butyrate;
- (20) dipipanone;

- 264.21 (21) ethylmethylthiambutene;
- 264.22 (22) etonitazene;
- 264.23 (23) etoxeridine;
- 264.24 (24) furethidine;
- 264.25 (25) hydroxypethidine;
- 264.26 (26) ketobemidone;
- 264.27 (27) levomoramide;
- 265.1 (28) levophenacylmorphane;
- 265.2 (29) 3-methylfentanyl;
- 265.3 (30) acetyl-alpha-methylfentanyl;
- 265.4 (31) alpha-methylthiofentanyl;
- 265.5 (32) benzylfentanyl beta-hydroxyfentanyl;
- 265.6 (33) beta-hydroxy-3-methylfentanyl;
- 265.7 (34) 3-methylthiofentanyl;
- 265.8 (35) thenylfentanyl;
- 265.9 (36) thiofentanyl;
- 265.10 (37) para-fluorofentanyl;
- 265.11 (38) morpheridine;
- 265.12 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 265.13 (40) noracymethadol;
- 265.14 (41) norlevorphanol;
- 265.15 (42) normethadone;
- 265.16 (43) norpipanone;
- 265.17 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 265.18 (45) phenadoxone;
- 265.19 (46) phenampromide;
- 265.20 (47) phenomorphan;
- 265.21 (48) phenoperidine;

- 265.22 (49) piritramide;
- 265.23 (50) proheptazine;
- 265.24 (51) properidine;
- 265.25 (52) propiram;
- 265.26 (53) racemoramide;
- 265.27 (54) tilidine;
- 266.1 (55) trimeperidine;
- 266.2 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 266.3 (57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
- 266.4 methylbenzamide(U47700);
- 266.5 (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
- 266.6 (59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol);
- 266.7 (60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl
- 266.8 fentanyl);
- 266.9 (61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
- 266.10 (62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
- 266.11 (63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl
- 266.12 fentanyl);
- 266.13 (64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
- 266.14 (65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
- 266.15 (66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide
- 266.16 (para-chloroisobutyryl fentanyl);
- 266.17 (67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl
- 266.18 fentanyl);
- 266.19 (68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide
- 266.20 (para-methoxybutyryl fentanyl);
- 266.21 (69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
- 266.22 (70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl
- 266.23 fentanyl or para-fluoroisobutyryl fentanyl);
- 266.24 (71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or
- 266.25 acryloylfentanyl);

266.26 (72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl
266.27 fentanyl);

266.28 (73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl
266.29 or 2-fluorofentanyl);

267.1 (74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide
267.2 (tetrahydrofuran-2-yl)fentanyl; ~~and~~

267.3 (75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers,
267.4 esters and ethers, meaning any substance not otherwise listed under another federal
267.5 Administration Controlled Substance Code Number or not otherwise listed in this section,
267.6 and for which no exemption or approval is in effect under section 505 of the Federal Food,
267.7 Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related
267.8 to fentanyl by one or more of the following modifications:

267.9 (i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether
267.10 or not further substituted in or on the monocycle;

267.11 (ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo,
267.12 haloalkyl, amino, or nitro groups;

267.13 (iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether,
267.14 hydroxyl, halo, haloalkyl, amino, or nitro groups;

267.15 (iv) replacement of the aniline ring with any aromatic monocycle whether or not further
267.16 substituted in or on the aromatic monocycle; or

267.17 (v) replacement of the N-propionyl group by another acyl group;

267.18 (76) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-
267.19 dihydro-2H-benzo[d]imidazol-2-one (bromophine);

267.20 (77) 4'-methyl acetyl fentanyl;

267.21 (78) beta-hydroxythiofentanyl;

267.22 (79) beta-methyl fentanyl;

267.23 (80) beta'-phenyl fentanyl;

267.24 (81) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);

267.25 (82) cyclopropyl fentanyl
267.26 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

267.27 (83) fentanyl carbamate;

267.28 (84) isotonitazene (N,N-diethyl-2-(2-(4
267.29 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);

- 267.30 (85) para-fluoro furanyl fentanyl;
- 268.1 (86) para-methylfentanyl;
- 268.2 (87) phenyl fentanyl;
- 268.3 (88) ortho-fluoroacryl fentanyl;
- 268.4 (89) ortho-fluorobutyryl fentanyl;
- 268.5 (90) ortho-fluoroisobutyryl fentanyl;
- 268.6 (91) ortho-methyl acetylfentanyl;
- 268.7 (92) thiofuranyl fentanyl;
- 268.8 (93) metonitazene
- 268.9 (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);
- 268.10 (94) metodesnitazene
- 268.11 (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
- 268.12 (95) etodesnitazene; etazene
- 268.13 (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
- 268.14 (96) protonitazene
- 268.15 (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);
- 268.16 (97) butonitazene
- 268.17 (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
- 268.18 (98) flunitazene
- 268.19 (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); and
- 268.20 (99) N-pyrrolidino etonitazene; etonitazepyne
- 268.21 (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).
- 268.22 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
- 268.23 and salts of isomers, unless specifically excepted or unless listed in another schedule,
- 268.24 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
- 268.25 (1) acetorphine;
- 268.26 (2) acetyldihydrocodeine;
- 268.27 (3) benzylmorphine;
- 268.28 (4) codeine methylbromide;
- 268.29 (5) codeine-n-oxide;
- 269.1 (6) cyprenorphine;

- 269.2 (7) desomorphine;
- 269.3 (8) dihydromorphine;
- 269.4 (9) drotebanol;
- 269.5 (10) etorphine;
- 269.6 (11) heroin;
- 269.7 (12) hydromorphinol;
- 269.8 (13) methyl-desorphine;
- 269.9 (14) methyl dihydromorphine;
- 269.10 (15) morphine methylbromide;
- 269.11 (16) morphine methylsulfonate;
- 269.12 (17) morphine-n-oxide;
- 269.13 (18) myrophine;
- 269.14 (19) nicocodeine;
- 269.15 (20) nicomorphine;
- 269.16 (21) normorphine;
- 269.17 (22) pholcodine; and
- 269.18 (23) thebacon.
- 269.19 (d) Hallucinogens. Any material, compound, mixture or preparation which contains any
- 269.20 quantity of the following substances, their analogs, salts, isomers (whether optical, positional,
- 269.21 or geometric), and salts of isomers, unless specifically excepted or unless listed in another
- 269.22 schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
- 269.23 possible:
- 269.24 (1) methylenedioxy amphetamine;
- 269.25 (2) methylenedioxymethamphetamine;
- 269.26 (3) methylenedioxy-N-ethylamphetamine (MDEA);
- 269.27 (4) n-hydroxy-methylenedioxyamphetamine;
- 269.28 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- 270.1 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- 270.2 (7) 4-methoxyamphetamine;

- 270.3 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- 270.4 (9) alpha-ethyltryptamine;
- 270.5 (10) bufotenine;
- 270.6 (11) diethyltryptamine;
- 270.7 (12) dimethyltryptamine;
- 270.8 (13) 3,4,5-trimethoxyamphetamine;
- 270.9 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- 270.10 (15) ibogaine;
- 270.11 (16) lysergic acid diethylamide (LSD);
- 270.12 (17) mescaline;
- 270.13 (18) parahexyl;
- 270.14 (19) N-ethyl-3-piperidyl benzilate;
- 270.15 (20) N-methyl-3-piperidyl benzilate;
- 270.16 (21) psilocybin;
- 270.17 (22) psilocyn;
- 270.18 (23) tenocyclidine (TPCP or TCP);
- 270.19 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- 270.20 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
- 270.21 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- 270.22 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- 270.23 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- 270.24 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- 270.25 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- 270.26 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- 270.27 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 271.1 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 271.2 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 271.3 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);

- 271.4 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 271.5 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 271.6 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 271.7 (2-CB-FLY);
- 271.8 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 271.9 (40) alpha-methyltryptamine (AMT);
- 271.10 (41) N,N-diisopropyltryptamine (DiPT);
- 271.11 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 271.12 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 271.13 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 271.14 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 271.15 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 271.16 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 271.17 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 271.18 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
- 271.19 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 271.20 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
- 271.21 (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
- 271.22 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 271.23 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 271.24 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 271.25 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 271.26 (57) methoxetamine (MXE);
- 271.27 (58) 5-iodo-2-aminoindane (5-IAI);
- 272.1 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 272.2 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- 272.3 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- 272.4 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);

- 272.5 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 272.6 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
- 272.7 (65) N,N-Dipropyltryptamine (DPT);
- 272.8 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
- 272.9 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
- 272.10 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
- 272.11 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
- 272.12 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethyl norketamine,
- 272.13 ethketamine, NENK);
- 272.14 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
- 272.15 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
- 272.16 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
- 272.17 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
- 272.18 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
- 272.19 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
- 272.20 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
- 272.21 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
- 272.22 Church, and members of the American Indian Church are exempt from registration. Any
- 272.23 person who manufactures peyote for or distributes peyote to the American Indian Church,
- 272.24 however, is required to obtain federal registration annually and to comply with all other
- 272.25 requirements of law.
- 272.26 (f) Central nervous system depressants. Unless specifically excepted or unless listed in
- 272.27 another schedule, any material compound, mixture, or preparation which contains any
- 272.28 quantity of the following substances, their analogs, salts, isomers, and salts of isomers
- 272.29 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
- 272.30 (1) mecloqualone;
- 273.1 (2) methaqualone;
- 273.2 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
- 273.3 (4) flunitrazepam;
- 273.4 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,
- 273.5 methoxyketamine);
- 273.6 (6) tianeptine;

- 273.7 (7) clonazolam;
- 273.8 (8) etizolam;
- 273.9 (9) flubromazolam; and
- 273.10 (10) flubromazepam.
- 273.11 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
- 273.12 material compound, mixture, or preparation which contains any quantity of the following
- 273.13 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the
- 273.14 analogs, salts, isomers, and salts of isomers is possible:
- 273.15 (1) aminorex;
- 273.16 (2) cathinone;
- 273.17 (3) fenethylline;
- 273.18 (4) methcathinone;
- 273.19 (5) methylaminorex;
- 273.20 (6) N,N-dimethylamphetamine;
- 273.21 (7) N-benzylpiperazine (BZP);
- 273.22 (8) methylmethcathinone (mephedrone);
- 273.23 (9) 3,4-methylenedioxy-N-methylcathinone (methyldone);
- 273.24 (10) methoxymethcathinone (methedrone);
- 273.25 (11) methylenedioxypropylvalerone (MDPV);
- 273.26 (12) 3-fluoro-N-methylcathinone (3-FMC);
- 273.27 (13) methylethcathinone (MEC);
- 273.28 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- 274.1 (15) dimethylmethcathinone (DMMC);
- 274.2 (16) fluoroamphetamine;
- 274.3 (17) fluoromethamphetamine;
- 274.4 (18) α -methylaminobutyrophenone (MABP or buphedrone);
- 274.5 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
- 274.6 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);

- 274.7 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
274.8 naphyrone);
- 274.9 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
- 274.10 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
- 274.11 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
- 274.12 (25) 4-methyl-N-ethylcathinone (4-MEC);
- 274.13 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
- 274.14 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 274.15 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
- 274.16 (29) 4-fluoro-N-methylcathinone (4-FMC);
- 274.17 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
- 274.18 (31) alpha-pyrrolidinobutiophenone (α -PBP);
- 274.19 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
- 274.20 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
- 274.21 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
- 274.22 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
- 274.23 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
- 274.24 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
- 274.25 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP);
- 274.26 (39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone);
274.27 ~~and~~
- 275.1 (40) any other substance, except bupropion or compounds listed under a different
275.2 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
275.3 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
275.4 compound is further modified in any of the following ways:
- 275.5 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
275.6 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
275.7 system by one or more other univalent substituents;
- 275.8 (ii) by substitution at the 3-position with an acyclic alkyl substituent;
- 275.9 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
275.10 methoxybenzyl groups; or

- 275.11 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure;
- 275.12 (41) 4,4'-dimethylaminorex (4,4'-DMAR;
- 275.13 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazoline);
- 275.14 (42) 4-chloro-alpha-pyrrolidinovalerophenone (4-chloro-A-PVP);
- 275.15 (43) para-methoxymethamphetamine (PMMA),
- 275.16 1-(4-methoxyphenyl)-N-methylpropan-2-amine; and
- 275.17 (44) N-ethylhexedrone.
- 275.18 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
- 275.19 excepted or unless listed in another schedule, any natural or synthetic material, compound,
- 275.20 mixture, or preparation that contains any quantity of the following substances, their analogs,
- 275.21 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
- 275.22 of the isomers, esters, ethers, or salts is possible:
- 275.23 (1) marijuana;
- 275.24 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, except
- 275.25 that tetrahydrocannabinols do not include any material, compound, mixture, or preparation
- 275.26 that qualifies as industrial hemp as defined in section 18K.02, subdivision 3; synthetic
- 275.27 equivalents of the substances contained in the cannabis plant or in the resinous extractives
- 275.28 of the plant; or synthetic substances with similar chemical structure and pharmacological
- 275.29 activity to those substances contained in the plant or resinous extract, including, but not
- 275.30 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
- 275.31 cis or trans tetrahydrocannabinol;
- 275.32 (3) synthetic cannabinoids, including the following substances:
- 276.1 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
- 276.2 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
- 276.3 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 276.4 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
- 276.5 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
- 276.6 naphthoylindoles include, but are not limited to:
- 276.7 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
- 276.8 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
- 276.9 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
- 276.10 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
- 276.11 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
- 276.12 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

- 276.13 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
- 276.14 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
- 276.15 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
- 276.16 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
- 276.17 (ii) Naphthylmethylinroles, which are any compounds containing a
- 276.18 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
- 276.19 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 276.20 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
- 276.21 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
- 276.22 ring to any extent. Examples of naphthylmethylinroles include, but are not limited to:
- 276.23 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
- 276.24 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
- 276.25 (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
- 276.26 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
- 276.27 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 276.28 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
- 276.29 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
- 276.30 naphthoylpyrroles include, but are not limited to,
- 276.31 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
- 277.1 (iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene
- 277.2 structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
- 277.3 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 277.4 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
- 277.5 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
- 277.6 naphthylmethylindenes include, but are not limited to,
- 277.7 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
- 277.8 (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
- 277.9 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
- 277.10 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 277.11 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
- 277.12 extent, whether or not substituted in the phenyl ring to any extent. Examples of
- 277.13 phenylacetylindoles include, but are not limited to:
- 277.14 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
- 277.15 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
- 277.16 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
- 277.17 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).

277.18 (vi) Cyclohexylphenols, which are compounds containing a
277.19 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
277.20 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
277.21 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
277.22 in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
277.23 limited to:

277.24 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);

277.25 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
277.26 (Cannabicyclohexanol or CP 47,497 C8 homologue);

277.27 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
277.28 -phenol (CP 55,940).

277.29 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
277.30 with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
277.31 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
277.32 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
278.1 extent and whether or not substituted in the phenyl ring to any extent. Examples of
278.2 benzoylindoles include, but are not limited to:

278.3 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);

278.4 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);

278.5 (C) (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
278.6 48,098 or Pravadoline).

278.7 (viii) Others specifically named:

278.8 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
278.9 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);

278.10 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
278.11 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);

278.12 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
278.13 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);

278.14 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);

278.15 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
278.16 (XLR-11);

278.17 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
278.18 (AKB-48(APINACA));

278.19 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
278.20 (5-Fluoro-AKB-48);

- 278.21 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
- 278.22 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
- 278.23 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide
278.24 (AB-PINACA);
- 278.25 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
278.26 1H-indazole-3-carboxamide (AB-FUBINACA);
- 278.27 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
278.28 indazole-3-carboxamide(AB-CHMINACA);
- 278.29 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate
278.30 (5-fluoro-AMB);
- 279.1 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 279.2 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
279.3 (FUBIMINA);
- 279.4 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
279.5 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 279.6 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
279.7 -1H-indole-3-carboxamide (5-fluoro-ABICA);
- 279.8 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
279.9 -1H-indole-3-carboxamide;
- 279.10 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
279.11 -1H-indazole-3-carboxamide;
- 279.12 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
- 279.13 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
279.14 H-indazole-3-carboxamide (MAB-CHMINACA);
- 279.15 (V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
279.16 (ADB-PINACA);
- 279.17 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 279.18 (X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
279.19 3-carboxamide. (APP-CHMINACA);
- 279.20 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
- 279.21 (Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
- 279.22 (ix) Additional substances specifically named:

279.23 (A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
279.24 H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);

279.25 (B) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide
279.26 (4-CN-Cumyl-Butinaca);

279.27 (C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);

279.28 (D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1
279.29 H-indazole-3-carboxamide (5F-ABPINACA);

280.1 (E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
280.2 (MDMB CHMICA);

280.3 (F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
280.4 (5F-ADB; 5F-MDMB-PINACA); ~~and~~

280.5 (G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)
280.6 1H-indazole-3-carboxamide (ADB-FUBINACA);

280.7 (H) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;

280.8 (I) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;

280.9 (J) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;

280.10 (K) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

280.11 (L) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;

280.12 (M) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate;

280.13 (N) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; and

280.14 (O) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide.

280.15 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
280.16 for human consumption.

280.17 **EFFECTIVE DATE.** This section is effective the day following final enactment.

280.18 Sec. 2. Minnesota Statutes 2022, section 152.02, subdivision 3, is amended to read:

280.19 Subd. 3. **Schedule II.** (a) Schedule II consists of the substances listed in this subdivision.

280.20 (b) Unless specifically excepted or unless listed in another schedule, any of the following
280.21 substances whether produced directly or indirectly by extraction from substances of vegetable
280.22 origin or independently by means of chemical synthesis, or by a combination of extraction
280.23 and chemical synthesis:

280.24 (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
280.25 opiate.

- 280.26 (i) Excluding:
- 280.27 (A) apomorphine;
- 280.28 (B) thebaine-derived butorphanol;
- 280.29 (C) dextrophan;
- 281.1 (D) nalbuphine;
- 281.2 (E) nalmeffene;
- 281.3 (F) naloxegol;
- 281.4 (G) naloxone;
- 281.5 (H) naltrexone; and
- 281.6 (I) their respective salts;
- 281.7 (ii) but including the following:
- 281.8 (A) opium, in all forms and extracts;
- 281.9 (B) codeine;
- 281.10 (C) dihydroetorphine;
- 281.11 (D) ethylmorphine;
- 281.12 (E) etorphine hydrochloride;
- 281.13 (F) hydrocodone;
- 281.14 (G) hydromorphone;
- 281.15 (H) metopon;
- 281.16 (I) morphine;
- 281.17 (J) oxycodone;
- 281.18 (K) oxymorphone;
- 281.19 (L) thebaine;
- 281.20 (M) oripavine;
- 281.21 (2) any salt, compound, derivative, or preparation thereof which is chemically equivalent
- 281.22 or identical with any of the substances referred to in clause (1), except that these substances
- 281.23 shall not include the isoquinoline alkaloids of opium;
- 281.24 (3) opium poppy and poppy straw;

281.25 (4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves
281.26 (including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers
281.27 and derivatives), and any salt, compound, derivative, or preparation thereof which is
281.28 chemically equivalent or identical with any of these substances, except that the substances
282.1 shall not include decocainized coca leaves or extraction of coca leaves, which extractions
282.2 do not contain cocaine or ecgonine;

282.3 (5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid,
282.4 or powder form which contains the phenanthrene alkaloids of the opium poppy).

282.5 (c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
282.6 of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule,
282.7 whenever the existence of such isomers, esters, ethers and salts is possible within the specific
282.8 chemical designation:

282.9 (1) alfentanil;

282.10 (2) alphaprodine;

282.11 (3) anileridine;

282.12 (4) bezitramide;

282.13 (5) bulk dextropropoxyphene (nondosage forms);

282.14 (6) carfentanil;

282.15 (7) dihydrocodeine;

282.16 (8) dihydromorphinone;

282.17 (9) diphenoxylate;

282.18 (10) fentanyl;

282.19 (11) isomethadone;

282.20 (12) levo-alpha-acetylmethadol (LAAM);

282.21 (13) levomethorphan;

282.22 (14) levorphanol;

282.23 (15) metazocine;

282.24 (16) methadone;

282.25 (17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

282.26 (18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic
282.27 acid;

- 282.28 (19) pethidine;
- 282.29 (20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
- 283.1 (21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
- 283.2 (22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 283.3 (23) phenazocine;
- 283.4 (24) piminodine;
- 283.5 (25) racemethorphan;
- 283.6 (26) racemorphan;
- 283.7 (27) remifentanil;
- 283.8 (28) sufentanil;
- 283.9 (29) tapentadol;
- 283.10 (30) 4-Anilino-N-phenethylpiperidine;
- 283.11 (31) oliceridine;
- 283.12 (32) norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide).
- 283.13 (d) Unless specifically excepted or unless listed in another schedule, any material,
- 283.14 compound, mixture, or preparation which contains any quantity of the following substances
- 283.15 having a stimulant effect on the central nervous system:
- 283.16 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 283.17 (2) methamphetamine, its salts, isomers, and salts of its isomers;
- 283.18 (3) phenmetrazine and its salts;
- 283.19 (4) methylphenidate;
- 283.20 (5) lisdexamfetamine.
- 283.21 (e) Unless specifically excepted or unless listed in another schedule, any material,
- 283.22 compound, mixture, or preparation which contains any quantity of the following substances
- 283.23 having a depressant effect on the central nervous system, including its salts, isomers, and
- 283.24 salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible
- 283.25 within the specific chemical designation:
- 283.26 (1) amobarbital;
- 283.27 (2) glutethimide;
- 283.28 (3) secobarbital;

- 283.29 (4) pentobarbital;
- 284.1 (5) phencyclidine;
- 284.2 (6) phencyclidine immediate precursors:
- 284.3 (i) 1-phenylcyclohexylamine;
- 284.4 (ii) 1-piperidinocyclohexanecarbonitrile;
- 284.5 (7) phenylacetone.
- 284.6 (f) Cannabinoids:
- 284.7 (1) nabilone;
- 284.8 (2) dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution
- 284.9 in a drug product approved for marketing by the United States Food and Drug Administration.
- 284.10 **EFFECTIVE DATE.** This section is effective the day following final enactment.
- 284.11 Sec. 3. Minnesota Statutes 2022, section 152.02, subdivision 5, is amended to read:
- 284.12 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this subdivision.
- 284.13 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
- 284.14 any material, compound, mixture, or preparation containing any of the following narcotic
- 284.15 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
- 284.16 as follows:
- 284.17 (1) not more than one milligram of difenoxin and not less than 25 micrograms of atropine
- 284.18 sulfate per dosage unit;
- 284.19 (2) dextropropoxyphene (Darvon and Darvocet);
- 284.20 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and
- 284.21 geometric isomers, and salts of these isomers (including tramadol);
- 284.22 (4) eluxadolone;
- 284.23 (5) pentazocine; and
- 284.24 (6) butorphanol (including its optical isomers).
- 284.25 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
- 284.26 material, compound, mixture, or preparation containing any quantity of the following
- 284.27 substances, including its salts, isomers, and salts of isomers whenever the existence of the
- 284.28 salts, isomers, and salts of isomers is possible:
- 284.29 (1) alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);
- 285.1 (2) alprazolam;

- 285.2 (3) barbital;
- 285.3 (4) bromazepam;
- 285.4 (5) camazepam;
- 285.5 (6) carisoprodol;
- 285.6 (7) chloral betaine;
- 285.7 (8) chloral hydrate;
- 285.8 (9) chlordiazepoxide;
- 285.9 (10) clobazam;
- 285.10 (11) clonazepam;
- 285.11 (12) clorazepate;
- 285.12 (13) clotiazepam;
- 285.13 (14) cloxazolam;
- 285.14 (15) delorazepam;
- 285.15 (16) diazepam;
- 285.16 (17) dichloralphenazone;
- 285.17 (18) estazolam;
- 285.18 (19) ethchlorvynol;
- 285.19 (20) ethinamate;
- 285.20 (21) ethyl loflazepate;
- 285.21 (22) fludiazepam;
- 285.22 (23) flurazepam;
- 285.23 (24) fospropofol;
- 285.24 (25) halazepam;
- 285.25 (26) haloxazolam;
- 285.26 (27) ketazolam;
- 285.27 (28) loprazolam;
- 286.1 (29) lorazepam;
- 286.2 (30) lormetazepam mebutamate;

- 286.3 (31) medazepam;
- 286.4 (32) meprobamate;
- 286.5 (33) methohexital;
- 286.6 (34) methylphenobarbital;
- 286.7 (35) midazolam;
- 286.8 (36) nimetazepam;
- 286.9 (37) nitrazepam;
- 286.10 (38) nordiazepam;
- 286.11 (39) oxazepam;
- 286.12 (40) oxazolam;
- 286.13 (41) paraldehyde;
- 286.14 (42) petrichloral;
- 286.15 (43) phenobarbital;
- 286.16 (44) pinazepam;
- 286.17 (45) prazepam;
- 286.18 (46) quazepam;
- 286.19 (47) suvorexant;
- 286.20 (48) temazepam;
- 286.21 (49) tetrazepam;
- 286.22 (50) triazolam;
- 286.23 (51) zaleplon;
- 286.24 (52) zolpidem;
- 286.25 (53) zopiclone;
- 286.26 (54) brexanolone (3 α -hydroxy-5 α -pregnan-20-one);
- 286.27 (55) lemborexant;
- 287.1 (56) remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid).

- 287.2 (d) Any material, compound, mixture, or preparation which contains any quantity of the
287.3 following substance including its salts, isomers, and salts of such isomers, whenever the
287.4 existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
- 287.5 (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any
287.6 material, compound, mixture, or preparation which contains any quantity of the following
287.7 substances having a stimulant effect on the central nervous system, including its salts,
287.8 isomers, and salts of isomers:
- 287.9 (1) cathine (norpseudoephedrine);
- 287.10 (2) diethylpropion;
- 287.11 (3) fencamfamine;
- 287.12 (4) fenproporex;
- 287.13 (5) mazindol;
- 287.14 (6) mefenorex;
- 287.15 (7) modafinil;
- 287.16 (8) pemoline (including organometallic complexes and chelates thereof);
- 287.17 (9) phentermine;
- 287.18 (10) pipradol;
- 287.19 (11) sibutramine;
- 287.20 (12) SPA (1-dimethylamino-1,2-diphenylethane)-₂
- 287.21 (13) serdexmethylphenidate;
- 287.22 (14) solriamfetol (2-amino-3-phenylpropyl car-bamate; benzenepropanol, beta-amino-,
287.23 carbamate (ester)).
- 287.24 (f) lorcaserin.
- 287.25 **EFFECTIVE DATE.** This section is effective the day following final enactment.
- 287.26 Sec. 4. Minnesota Statutes 2022, section 152.02, subdivision 6, is amended to read:
- 287.27 Subd. 6. **Schedule V; restrictions on methamphetamine precursor drugs.** (a) As used
287.28 in this subdivision, the following terms have the meanings given:
- 288.1 (1) "methamphetamine precursor drug" means any compound, mixture, or preparation
288.2 intended for human consumption containing ephedrine or pseudoephedrine as its sole active
288.3 ingredient or as one of its active ingredients; and

- 288.4 (2) "over-the-counter sale" means a retail sale of a drug or product but does not include
288.5 the sale of a drug or product pursuant to the terms of a valid prescription.
- 288.6 (b) The following items are listed in Schedule V:
- 288.7 (1) any compound, mixture, or preparation containing any of the following limited
288.8 quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal
288.9 ingredients in sufficient proportion to confer upon the compound, mixture or preparation
288.10 valuable medicinal qualities other than those possessed by the narcotic drug alone:
- 288.11 (i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
288.12 (ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
288.13 (iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
288.14 atropine sulfate per dosage unit;
- 288.15 (iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or
288.16 (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine
288.17 sulfate per dosage unit.
- 288.18 (2) Stimulants. Unless specifically exempted or excluded or unless listed in another
288.19 schedule, any material, compound, mixture, or preparation that contains any quantity of the
288.20 following substance having a stimulant effect on the central nervous system, including its
288.21 salts, isomers, and salts of isomers: pyrovalerone.
- 288.22 (3) Depressants. Unless specifically exempted or excluded or unless listed in another
288.23 schedule, any material, compound, mixture, or preparation that contains any quantity of the
288.24 following substance having a depressant effect on the central nervous system, including its
288.25 salts, isomers, and salts of isomers:
- 288.26 (i) ezogabine;
288.27 (ii) pregabalin;
288.28 (iii) lacosamide-;
- 288.29 (iv) cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl]carbamate.
- 288.30 (4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine
288.31 as its sole active ingredient or as one of its active ingredients.
- 289.1 (c) No person may sell in a single over-the-counter sale more than two packages of a
289.2 methamphetamine precursor drug or a combination of methamphetamine precursor drugs
289.3 or any combination of packages exceeding a total weight of six grams, calculated as the
289.4 base.
- 289.5 (d) Over-the-counter sales of methamphetamine precursor drugs are limited to:

289.6 (1) packages containing not more than a total of three grams of one or more
289.7 methamphetamine precursor drugs, calculated in terms of ephedrine base or pseudoephedrine
289.8 base; or

289.9 (2) for nonliquid products, sales in blister packs, where each blister contains not more
289.10 than two dosage units, or, if the use of blister packs is not technically feasible, sales in unit
289.11 dose packets or pouches.

289.12 (e) A business establishment that offers for sale methamphetamine precursor drugs in
289.13 an over-the-counter sale shall ensure that all packages of the drugs are displayed behind a
289.14 checkout counter where the public is not permitted and are offered for sale only by a licensed
289.15 pharmacist, a registered pharmacy technician, or a pharmacy clerk. The establishment shall
289.16 ensure that the person making the sale requires the buyer:

289.17 (1) to provide photographic identification showing the buyer's date of birth; and

289.18 (2) to sign a written or electronic document detailing the date of the sale, the name of
289.19 the buyer, and the amount of the drug sold.

289.20 A document described under clause (2) must be retained by the establishment for at least
289.21 three years and must at all reasonable times be open to the inspection of any law enforcement
289.22 agency.

289.23 Nothing in this paragraph requires the buyer to obtain a prescription for the drug's
289.24 purchase.

289.25 (f) No person may acquire through over-the-counter sales more than six grams of
289.26 methamphetamine precursor drugs, calculated as the base, within a 30-day period.

289.27 (g) No person may sell in an over-the-counter sale a methamphetamine precursor drug
289.28 to a person under the age of 18 years. It is an affirmative defense to a charge under this
289.29 paragraph if the defendant proves by a preponderance of the evidence that the defendant
289.30 reasonably and in good faith relied on proof of age as described in section 340A.503,
289.31 subdivision 6.

290.1 (h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of a
290.2 misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to
290.3 payment of a fine of not more than \$1,000, or both.

290.4 (i) An owner, operator, supervisor, or manager of a business establishment that offers
290.5 for sale methamphetamine precursor drugs whose employee or agent is convicted of or
290.6 charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal penalties
290.7 for violating any of those paragraphs if the person:

290.8 (1) did not have prior knowledge of, participate in, or direct the employee or agent to
290.9 commit the violation; and

290.10 (2) documents that an employee training program was in place to provide the employee
290.11 or agent with information on the state and federal laws and regulations regarding
290.12 methamphetamine precursor drugs.

290.13 (j) Any person employed by a business establishment that offers for sale
290.14 methamphetamine precursor drugs who sells such a drug to any person in a suspicious
290.15 transaction shall report the transaction to the owner, supervisor, or manager of the
290.16 establishment. The owner, supervisor, or manager may report the transaction to local law
290.17 enforcement. A person who reports information under this subdivision in good faith is
290.18 immune from civil liability relating to the report.

290.19 (k) Paragraphs (b) to (j) do not apply to:

290.20 (1) pediatric products labeled pursuant to federal regulation primarily intended for
290.21 administration to children under 12 years of age according to label instructions;

290.22 (2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as
290.23 being manufactured in a manner that prevents the drug from being used to manufacture
290.24 methamphetamine;

290.25 (3) methamphetamine precursor drugs in gel capsule or liquid form; or

290.26 (4) compounds, mixtures, or preparations in powder form where pseudoephedrine
290.27 constitutes less than one percent of its total weight and is not its sole active ingredient.

290.28 (l) The Board of Pharmacy, in consultation with the Department of Public Safety, shall
290.29 certify methamphetamine precursor drugs that meet the requirements of paragraph (k),
290.30 clause (2), and publish an annual listing of these drugs.

290.31 (m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy
290.32 pursuant to sections ~~151.42 to 151.51~~ 151.43 to 151.471 and registered with and regulated
291.1 by the United States Drug Enforcement Administration are exempt from the
291.2 methamphetamine precursor drug storage requirements of this section.

291.3 (n) This section preempts all local ordinances or regulations governing the sale by a
291.4 business establishment of over-the-counter products containing ephedrine or
291.5 pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.

291.6 **EFFECTIVE DATE.** This section is effective the day following final enactment.